As the Biden administration prepares to end the COVID-19 public health emergency on May 11, the FDA must decide what to do with dozens of temporary guidances issued during the public health emergency.

The company had planned to develop vaccines for several other conditions, including seasonal flu, rotavirus and norovirus infections.

The updated authorizations were supported by data from late-stage studies.